A CLINICAL TRIAL TO STUDY THE SAFETY, TOLERANCE AND IMMUNOGENIC RESPONSE TO MCV4, TDAP AND BIVALENT RLP2086 VACCINE WHEN GIVEN AT THE SAME TIME TO CHILDREN BETWEEN THE AGES OF 10 THROUGH 12 YEARS OF AGE: